Taken together, our results highlight the challenges to successfully incorporate mTOR inhibitors into the treatment regimen for GB and underline the importance of pre-clinical experimental settings that adequately mirror the conditions of the tumor microenvironment in order to assess the potential of pharmacological inhibitors as a therapeutic option. The gene discussed is MTOR; the disease is neoplasm.